To learn if gadopiclenol (a contrast agent) used during MRI scanning can help in the detection of early LMD.
Patients with tissue confirmed solid malignancy and standard of care brain MRI with equivocal results for LMD (questionable or possible) and negative LP CSF sampling or patients with high risk clinical LMD and negative brain MR and LP CSF sampling. Initially, we will target solid tumors, but if more patients are needed to meet the study power we will enroll liquid tumors.
Participants > 18 years of age.
Participants are able to consent.
Participants with CSF sampling positive for LMD or MR brain/spine with definitive evidence of LMD.
Participants with implantable devices that can not be scanned with MR safe mode for participant safety.
Pregnant participants or potentially pregnant participants are at risk of contrast on the fetus